Back to Search Start Over

Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers

Authors :
Robert W. Sauerwein
Charlie Weller
Myron M. Levine
Anna P. Durbin
Sheng Li Shi
Peter G. Kremsner
Philip R. Krause
Rosanna Lagos
M. Cristina Cassetti
John J. Treanor
Stanley A. Plotkin
Deborah King
Delese Mimi Darko
Halvor Sommerfelt
Yaseen M. Arabi
Vicente Estrada
Punnee Pitisuttithum
Sudhanshu Vrati
Euzebiusz Jamrozik
Ana Maria Henao Restrepo
Anastazia Older Aguilar
Shobana Balasingam
Kanta Subbarao
Salim Abdullah
Source :
Clinical Infectious Diseases, Clinical Infectious Diseases, 72, 2035-2041, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, Clinical Infectious Diseases, 72, 11, pp. 2035-2041
Publication Year :
2021

Abstract

WHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.

Details

ISSN :
10584838
Database :
OpenAIRE
Journal :
Clinical Infectious Diseases, Clinical Infectious Diseases, 72, 2035-2041, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, Clinical Infectious Diseases, 72, 11, pp. 2035-2041
Accession number :
edsair.doi.dedup.....314a6dfec0356d8d0f3712a8b8adbbbf